In the event of accidental overdosage, supportive measures, including gastric lavage with sodium bicarbonate, should be employed.
The recommended starting dose of Ketoconazole Tablets is a single daily administration of 200 mg (one tablet). In very serious infections or if clinical responsiveness is insufficient within the expected time, the dose of Ketoconazole Tablets may be increased to 400 mg (two tablets) once daily.
In small numbers of pediatric patients over 2 years of age, a single daily dose of 3.3 to 6.6 mg/kg has been used. Ketoconazole Tablets have not been studied in pediatric patients under 2 years of age.
There should be laboratory as well as clinical documentation of infection prior to starting ketoconazole therapy. Treatment should be continued until tests indicate that active fungal infection has subsided. Inadequate periods of treatment may yield poor response and lead to early recurrence of clinical symptoms. Minimum treatment for candidiasis is one or two weeks. Patients with chronic mucocutaneous candidiasis usually require maintenance therapy. Minimum treatment for the other indicated systemic mycoses is six months.
Minimum treatment for recalcitrant dermatophyte infections is four weeks in cases involving glabrous skin. Palmar and plantar infections may respond more slowly. Apparent cures may subsequently recur after discontinuation of therapy in some cases.
Ketoconazole Tablets USP 200 mg are available as white to off-white, round, scored tablets, imprinted “KET” over bisect “200″ on one side, and “APO” on the other side; supplied in bottles of 30 tablets (NDC 60505-0092-2), bottles of 100 tablets (NDC 60505-0092-0) and bottles of 1000 tablets (NDC 60505-0092-1).
Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature] .
Dispense in a tight, light-resistant container as defined in the USP.
KETOCONAZOLE TABLETS USP
Manufactured by: Manufactured for:
Apotex Inc. Apotex Corp.
Toronto, Ontario Weston, Florida
Canada M9L 1T9 33326
Revised: July 2004
Representative sample of labeling (see HOW SUPPLIED section for complete listing):
APOTEX CORP. NDC 60505-0092-2
30 bottle count
| KETOCONAZOLE |
|Labeler — Apotex Corp (845263701)|
|Registrant — Apotex Inc (209429182)|
|Apotex Inc||205576023||manufacture (60505-0092), analysis (60505-0092)|
Revised: 10/2012 Apotex Corp
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.